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ABSTRACT
SeveralstudiesrecognizedanoverlapbetweenCFS(chronicfatiguesyndrome)andPOTS(postural
tachycardia syndrome). We compared the autonomic and neurohormonal phenotype of POTS
patients with CFS (CFS–POTS) to those without CFS (non-CFS–POTS), to determine whether
CFS–POTS represents a unique clinical entity with a distinct pathophysiology. We recruited 58
patients with POTS, of which 47 were eligible to participate. A total of 93% of them reported
severe fatigue [CIS (Checklist of Individual Strength), fatigue subscale >36], and 64% (n=30)
fulﬁlled criteria for CFS (CFS–POTS). The prevalence of CFS symptoms (Centers for Disease
Control and Prevention criteria) was greater in the CFS–POTS group, but the pattern of
symptoms was similar in both groups. Physical functioning was low in both groups (RAND-
36 Health Survey, 40+ −4 compared with 33+ −3; P=0.153), despite more severe fatigue in
CFS–POTS patients (CIS fatigue subscale 51+ −1c o m p a r e dw i t h4 3 + −3; P=0.016). CFS–POTS
patientshadgreaterorthostatictachycardiathanthenon-CFS–POTSgroup(51+ −3comparedwith
40+ −4b e a t s / m i n ;P=0.030), greater low-frequency variability of BP (blood pressure; 6.3+ −0.7
compared with 4.8+ −1.0 mmHg2; P=0.019), greater BP recovery from early to late phase II of
the Valsalva manoeuvre (18+ −3 compared with 11+ −2 mmHg; P=0.041) and a higher supine
(1.5+ −0.2 compared with 1.0+ −0.3 ng/ml per·h; P=0.033) and upright (5.4+ −0.6 compared with
3.5+ −0.8 ng/ml per h; P=0.032) PRA (plasma renin activity). In conclusion, fatigue and CFS-
deﬁning symptoms are common in POTS patients. The majority of them met criteria for CFS.
CFS–POTS patients have higher markers of sympathetic activation, but are part of the spectrum
of POTS. Targeting this sympathetic activation should be considered in the treatment of these
patients.
Key words: autonomic nervous system, blood volume, chronic fatigue syndrome, orthostatic intolerance, postural tachycardia
syndrome (POTS), renin.
Abbreviations: AFT, autonomic function test; AngI, angiotensin I; BMI, body mass index; BP, blood pressure; BV, blood volume;
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heart rate; POTS, postural tachycardia syndrome; PRA, plasma renin activity; PV, plasma volume; QSART, quantitative sudomotor
axon reﬂex testing; RAAS, renin–angiotensin–aldosterone system.
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INTRODUCTION
CFS (chronic fatigue syndrome) is a disabling disorder
characterized by persistent or relapsing unexplained
fatigue,accompanied bycharacteristic physical,constitu-
tional and neuropsychological symptoms lasting at least
6 months [1]. The prevalence of CFS varies between
0.007 and 2.5% in the general population, and it is
about twice as common in women [2]. The aetiology and
pathophysiology of this syndrome remain unknown, but
the autonomic nervous system has been proposed to play
a role [3,4]. Clinical features of autonomic dysfunction
suchasorthostaticintolerance,increasedsweating,pallor,
sluggish pupillary responses, gastrointestinal symptoms
and frequency of micturition are often observed in
patients with CFS [5,6]. Particularly, neurally mediated
hypotensionandPOTS(posturaltachycardiasyndrome),
two forms of orthostatic intolerance, have been shown to
be prevalent in adults and children with CFS [7–11], and
ithasbeenproposedthatthehaemodynamicmechanisms
underlying these autonomic conditions may play a role
in the pathophysiology of CFS [4,6] and contribute to its
symptoms [9,11].
POTS is one of the most frequent forms of chronic
orthostatic intolerance in the general population [12],
with a 5:1 female/male ratio [13]. POTS is a disabling
condition characterized by excessive tachycardia and
symptoms upon standing that signiﬁcantly improve
by recumbency [14]. Nevertheless, non-orthostatic
symptoms, such as fatigue or CFS-related symptoms,
are often major complaints, and in some patients can
be chronic and overwhelming [15]. A substantial overlap
betweenPOTSandCFShasbeenconsistentlyreportedin
the literature [10,11,15,16]. The prevalence of POTS
in CFS patients has ranged from 19% [7] to 70% [10],
whereas studies in cohorts of patients selected for POTS
have shown a prevalence of chronic fatigue between
48 and 77% [15,17], and CFS between 17 and 23%
[17,18]. Furthermore, increased sympathetic activation
and low BVs (blood volumes) have been proposed
as pathophysiological mechanisms in both conditions
[4,11,19–21].Theaimofthepresentstudywastocompare
the clinical, autonomic and neurohumoral features of
POTS patients with and without CFS, to determine
whether POTS patients with CFS represent a unique
clinical entity with a distinct pathophysiology, or are a
subset of patients within the spectrum of POTS.
MATERIALS AND METHODS
Subjects
We studied 58 consecutive female patients with
POTS referred to Vanderbilt University Autonomic
Dysfunction Center for disabling orthostatic intolerance
between August 2006 and March 2010. A diagnosis
of POTS was based on the following criteria: (i) a
history of daily orthostatic symptoms for at least
6 months; (ii) HR (heart rate) increase of 30
beats/min within the ﬁrst 10 min of standing; (iii)
the absence of orthostatic hypotension [deﬁned as a
fall in BP (blood pressure) >20/10 mmHg]; and (iv)
the absence of conditions that can explain postural
tachycardia, such as acute dehydration, prolonged bed
rest or medication [13]. Patients were at least 18 years
old and all were screened with a comprehensive
medical history, physical examination, 12-lead ECG
and routine laboratory studies. Subjects with abnormal
renal function, liver function, haematological disease or
systemic illnesses that might affect autonomic function,
e.g. diabetes, cardiac arrhythmias, adrenocortical disease
or other known autonomic disorders, were excluded.
The Vanderbilt University Investigational Review Board
approved the present study, and written informed
consent was obtained from each subject before initiat-
ing the study (http://www.ClinicalTrials.gov identiﬁer
NCT00580619).
CFS: deﬁnition and classiﬁcation
To fulﬁl the case deﬁnition, fatigue was deﬁned as
unexplained, persistent fatigue present for 6 months
that was not mainly a result of exertion; was not
substantially relieved by rest, was of new onset (not
lifelong)andresultedinasigniﬁcantreductioninprevious
levels of activity [1]. CFS was deﬁned according to CDC
(Centers for Disease Control and Prevention) criteria [1],
and included a case-deﬁning fatigue associated with at
least four of the following ancillary symptoms: impaired
short-term memory or concentration, sore throat, tender
lymphadenopathy, muscle pain, joint pain, headaches of
a new type, sleep disturbance and post-exercise malaise
[1]. Patients with exclusionary medical or psychiatric
conditions for CFS were not included in the present
study [1]. As a result, ﬁve patients (two with eating
disorders, two with signiﬁcant fatigue associated with
β-blockers and one patient with juvenile rheumatoid
arthritis) were excluded. Six other patients with case-
deﬁning fatigue but insufﬁcient symptom criteria for
CFS (i.e. less than four ancillary symptoms) were not
included in the analysis because these patients cannot be
clearly differentiated from the CFS group [22]. Among
the remaining 47 patients who were enrolled in the study,
30 met CFS criteria (termed CFS–POTS) and the other
17 were classiﬁed as non-CFS–POTS.
General protocol
All subjects were admitted to the Vanderbilt General
ClinicalResearchCenterandwerefedalow-monoamine,
caffeine-freedietcontaining150 mM/lNa+ and70 mM/l
K+ per day. Medication affecting BP, BV and the
autonomic nervous system was withheld for 5h a l f -
livesbeforeadmission.Fludrocortisonewasdiscontinued
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for 5 days. All participants completed the following
evaluations: AFTs (autonomic function tests), posture
study with supine and upright catecholamines, and a
batteryofquestionnaires.Inaddition,asubsetofpatients
underwent BV assessment and QSART (quantitative
sudomotor axon reﬂex testing).
Evaluation of fatigue and functional
impairment
Fatigue severity was assessed by a subscale of the CIS
(Checklist of Individual Strength) [23] that measures
both general and physical fatigue; a score >36 represents
severe fatigue [24]. Functional impairment and general
health status were assessed by the use of the RAND-36
Health Survey that includes eight domains: limitations in
physical activities (physical functioning), role limitation
due to physical problems, bodily pain, emotional well-
being, role limitation due to emotional problems,
energy/fatigue,socialfunctioningandgeneralhealth[25].
Scores for each domain range from 0 to 100, with higher
scores reﬂecting better health status.
Posture study and AFTs
An orthostatic test was performed with patients fasted,
and while they remained supine after an overnight
rest, to evaluate haemodynamic and hormonal changes
on standing. An indwelling catheter was placed in
an antecubital vein at least 30 min before testing.
BP and HR were obtained using an automated
sphygmomanometer (Dinamap; GE Medical Systems
Information Technologies). Subjects were encouraged
to stand as long as possible to a maximum of 30 min.
During this period, they were allowed to sit at intervals if
presyncopal symptoms developed. Blood samples were
obtained for plasma noradrenaline (norepinephrine),
PRA (plasma renin activity) and aldosterone.
AFTs included the Valsalva manoeuvre and the cold
pressor test as described previously [26]. All tests were
performed in the morning, 2 h or more after a light
breakfast. BP and HR were obtained using an automated
oscillometric sphygmomanometer (Dinamap), ﬁnger
photoplethysmography (Finometer, FMS; or Nexﬁn,
BMEYE), and continuous ECG. Supine baseline data
collected during the Valsalva manoeuvre were digitized
and recorded using a WINDAQ data acquisition system
(14 Bit, 500 Hz; DI220; DATAQ;) and processed off-line
usingcustom-writtensoftwareinPV-Wavelanguage(PV-
Wave; Visual Numerics). Beat-to-beat values of BP and
R–R intervals were digitized and analysed to determine
the power spectra in the low-frequency (0.04–0.15 Hz)
and high-frequency (0.15–0.40 Hz) range, as described
previously [27].
BV assessment
We determined PV (plasma volume) in a subset of
28 patients (20 CFS–POTS and eight non-CFS–POTS
patients) by the indicator dye-dilution technique using
131I-labelled human serum albumin (Volumex; Daxor), as
described previously [21]. Total BV was calculated from
measured PV and haematocrit. Erythocyte volume was
calculatedasthedifferencebetweentotalBVandPV.Ideal
PV and total BV were determined for each individual
based on normative data considering height, weight and
gender [21].
QSART
Asubsetof31patients(21CFS–POTSandtennon-CFS–
POTS patients) underwent QSART testing to compare
the prevalence of neural sudomotor abnormalities
between these two groups. QSART testing was
performed using the QSweat device (WR Electronics), as
described previously [28]. Capsules were placed at four
standard sites: distal forearm, proximal leg, distal leg and
foot. A 10% acetylcholine solution was iontophoresed
using a current of 2.0 mA. Results were recorded in
microlitres of sweat volume. Results were deemed to
be abnormal if one or more sites were below the ﬁfth
percentile for age and gender using published normative
dataoriftherewasaproximaldistalgradientwithadistal
site<one-thirdofthevolumeoftheproximalsite.Results
were also analysed by raw sweat volume.
Hormone measurements
Plasma noradrenaline were collected in plastic syringes,
immediately transferred to chilled vacuum tubes with
sodium heparin (BD, Franklin Lakes, NJ, U.S.A.), and
placed on ice. Plasma was separated by centrifugation
at −4 ◦C and stored at −70 ◦C in collection tubes
with 6% GSH (Sigma) until the assay was performed.
Concentrationsofnoradrenalineweremeasuredbybatch
alumina extraction followed by HPLC for separation
with electrochemical detection and quantiﬁcation [29].
PRA was assessed by the conversion of angiotensinogen
into AngI (angiotensin I) and expressed as ng of AngI
produced/ml of plasma per h. Plasma aldosterone was
measured by RIA [21].
Statistical methods
Frequencytablesweregeneratedforcategoricalvariables.
Continuous variables are expressed as means+ −S.E.M.
Normal distribution of data was assessed using
the Kolmogorov–Smirnov test. Comparisons between
patients with CFS–POTS and non-CFS–POTS were
analysed by Student’s t tests if they had normal
distribution. Otherwise, a Mann–Whitney U test was
used. The χ2 test and Fisher’s exact test were used for
categorical comparisons of data.
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Table 1 Clinical characteristics of patients with CFS–POTS and non-CFS–POTS
Values are means+ −S.E.M., unless otherwise stated.
Clinical characteristics Non-CFS–POTS (n=17) CFS–POTS (n=30) P value
Age (years) 33+ −23 0 + −2 0.121
BMI (kg/m2)2 3 + −12 4 + −1 0.877
Duration of disease (months)∗ 55+ −14 72+ −11 0.231
Prior medication use†
β-Blockers (n) 11 (65%) 19 (63%) 0.925
Fludrocortisone acetate (n) 4 (24%) 11 (37%) 0.353
Haematocrit (%) 40+ −14 0 + −1 0.321
Na+ (mM/l) 139+ −0.6 140+ −0.4 0.296
K+ (mM/l) 4.0+ −0.1 3.9+ −0.1 0.480
Calculated plasma osmolality (mM/l) 286+ −1 288+ −1 0.301
Plasma creatinine (mg/dl) 0.8+ −0.03 0.8+ −0.02 0.420
∗Duration of disease calculated from the onset of orthostatic symptoms.
†Medications reported within 6 months before admission.
All the tests were two-tailed, and a P<0.05 was
considered signiﬁcant. Analyses were performed with
SPSS for Windows, version 17.0.
RESULTS
Patient characteristics and CFS symptoms
We recruited 58 patients with POTS, of which 47 were
eligible to participate. The majority of them (64%,
n=30) fulﬁlled criteria for CFS (CFS–POTS), whereas
the remainder (36%, n=17) were classiﬁed as non-CFS–
POTS. Clinical characteristics of both groups are shown
in Table 1. There was no signiﬁcant difference in age,
BMI (body mass index), serum electrolytes, calculated
osmolality or plasma creatinine between groups. CFS–
POTS patients tended to have a longer duration
of disease (estimated from the onset of orthostatic
symptoms) as compared with those with non-CFS–
POTS, but this trend did not reach statistical signiﬁcance
(P=0.231).Theproportionofpatientstakingβ-blockers
or ﬂudrocortisone acetate before admission was similar
between groups.
Fatigue and CFS-related symptoms
Severe fatigue (CIS, fatigue subscale >36) was observed
in 93% of POTS patients. By deﬁnition, all subjects with
CFS–POTSreportedseverefatigue(Figure1),whichwas
greater in severity than in those without CFS (51+ −1
compared with 43+ −3 respectively; P=0.016). The
majority of non-CFS–POTS patients (80%), however,
also experienced severe fatigue, but none of them met the
casedeﬁnitionoffatigue,eitherbecauseitwasreportedas
‘lifelong’ (82%, n=14), mainly related to exercise (53%,
n=9),non-disabling(29%,n=5)andlasting<6months
(29%, n=5).
Figure 1 Prevalence of severe fatigue and CFS-related
symptoms
Severe fatigue was deﬁned as a CIS fatigue severity subscale score >36.
∗P <0.05.
CFS-related symptoms were common in both groups.
The mean number of ancillary symptoms was 5.3+ −0.2
[median (interquartile range), 5 (4–7)] in patients with
CFS–POTS,and3.8+ −0.5[median(interquartilerange),4
(3–5)] in the non-CFS group. Only one non-CFS–POTS
patient had no CFS-related symptoms. The pattern of
case-deﬁning symptoms was similar in the two groups.
Unrefreshing sleep, impaired memory or concentration
and muscle pain were the most common symptoms in
both groups; whereas joint pain, tender lymph nodes
and sore throat were the least prevalent (Figure 1). CFS–
POTS patients, however, had a higher prevalence of sleep
disturbances, muscle pain, post-exertional fatigue and
headaches as compared with those without CFS.
Consistent with the CFS deﬁnition, the CFS–
POTS group had signiﬁcantly lower scores on the
fatigue/energy domain, indicating more severe fatigue
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Table 2 General health status and functional impairment (RAND-36 health survey)
Scores are means+ −S.E.M.; range 0–100. Low scores indicate more severe conditions.
Scale Non-CFS–POTS (n=17) CFS–POTS (n=30) P value
Physical health
Physical functioning 40.1+ −4.1 32.8+ −3.1 0.153
Role limitation due to physical health 2.9+ −2.9 0.9+ −0.9 0.676
Bodily pain 65.8+ −6.1 54.1+ −3.7 0.057
Mental health
Emotional well-being 66.1+ −4.9 68.0+ −3.4 0.796
Role limitation due to emotional problems 39.6+ −11.5 37.9+ −8.6 0.844
Other
General health 31.8+ −3.7 27.8+ −2.4 0.351
Energy/fatigue 31.5+ −6.1 16.8+ −3.0 0.037
Social functioning 36.8+ −5.9 32.6+ −5.1 0.499
(Table 2). Most notably, both groups reported extremely
low scores in the role limitation due to physical health
domain, underscoring their severe disability. There was
also a trend towards increased perception of bodily pain
(lower scores) in POTS patients with CFS, but did not
reach signiﬁcance (P=0.057).
Autonomic testing, power spectral
densities and neurohormonal proﬁle
Supine BP and HR were similar in the two groups
(Table3).Allpatientshadposturaltachycardiawithinthe
ﬁrst 10 min of upright posture, but ten (59%) non-CFS
and16(53%)CFS–POTSpatientscouldnotcompletethe
30-min test due to orthostatic symptoms. Of them, one
non-CFSandsixCFS–POTSpatientsdevelopedneurally
mediated hypotension after prolonged standing. The
meanstandingtime(i.e.orthostatictolerance)wassimilar
in both groups. After 10 min standing, both groups had
similar increases in HR (49+ −3 compared with 40+ −5
beats/min in the CFS–POTS and non-CFS–POTS group
respectively; P=0.114), in systolic BP (5+ −2 compared
with 4+ −3 mmHg in the CFS–POTS and non-CFS–
POTS group respectively; P=0.868) and in diastolic BP
(6+ −2a n d4 + −2 mmHg in the CFS–POTS and non-
CFS–POTSgrouprespectively;P=0.256).Atthetimeof
maximal orthostatic tolerance, HR had a greater increase
in CFS–POTS patients as compared with the non-CFS–
POTS group (P=0.030; Table 3), whereas BP remained
similar in the two groups (113/76+ −4/2 compared with
106/72+ −4/3 mmHg in the CFS–POTS and non-CFS–
POTS group respectively; P>0.05).
BothgroupshadanexaggerateddecreaseinsystolicBP
duringearly phase II of theValsalva manoeuvre (Table 3).
BP recovery from early to late phase II, however, was
greater in the CFS–POTS group (P=0.041; Table 3).
The pressor response to pain stimulus (cold pressor
test) did not differ between the two groups. Both the
high- and low-frequency components of HRV (heartrate
variability) at supine rest were greatly decreased in both
groups compared with normal controls (Table 3). CFS–
POTS patients had greater supine resting BP variability
in the low-frequency (LFSBP) component compared with
those with non-CFS–POTS (P=0.019; Table 3).
Patients with CFS–POTS and non-CFS–POTS had a
signiﬁcantincreaseinplasmanoradrenalinewithstanding
(P<0.01;Table3),butnodifferenceswerefoundbetween
groupsinsupineoruprightplasmanoradrenaline.Supine
and upright PRA were signiﬁcantly higher in the CFS–
POTS group compared with those with non-CFS–POTS
[supine, 1.5+ −0.2 compared with 1.0+ −0.3 ng/ml per
h respectively (P=0.033); upright, 5.4+ −0.6 compared
with 3.5+ −0.8 ng/ml per h respectively (P=0.032)]
(Figure 2A). Plasma aldosterone tended to be higher
in CFS–POTS compared with non-CFS–POTS patients
(Figure 2B), but the differences did not reach signiﬁcance
for either supine (6.8+ −1.3 compared with 4.9+ −1.0 ng/dl
respectively; P=0.506) or standing (19.4+ −2.4 compared
with 17.0+ −3.0 ng/dl respectively; P=0.626). There
was a trend towards lower supine aldosterone/PRA
ratios in CFS–POTS patients compared with the non-
CFS–POTS group (5.9+ −0.9 compared with 7.1+ −1.0
respectively; P=0.245) (Figure 2C), particularly upon
standing (4.4+ −0.5 compared with 6.5+ −1.0 respectively;
P=0.054).
BV
CFS–POTS and non-CFS–POTS patients had sim-
ilar PVs (2659+ −134 and 2787+ −130 ml respectively;
P=0.580). The calculated deﬁcit in PV compared with
normativedatawassimilarinbothgroups[−132+ −66 ml
(5.3+ −2.5%) and −36+ −119 ml (1.3+ −4.2%) in the
CFS–POTS and non-CFS–POTS group respectively;
P=0.458]. The proportion of subjects with PV deﬁcits
>8% was non-signiﬁcantly higher in CFS–POTS than
in the non-CFS–POTS group (35 compared with 25%
respectively).
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Table 3 Autonomic and neurohormonal proﬁle in CFS–POTS and non-CFS–POTS
Values are means+ −S.E.M. DBP, diastolic BP; SBP, systolic BP; LF, low frequency; HF, high frequency; RRI, R–R heart rate interval. Control values from the Autonomic
Dysfunction Center Database at Vanderbilt University are presented as a reference.
Non-CFS POTS CFS-POTS Controls
Test Value n Value nP value Value n
Orthostatic stress test
Supine
SBP (mmHg) 104+ −3 17 108+ −2 30 0.385 100+ −22 2
DBP (mmHg) 67+ −21 76 7 + −2 30 0.963 65+ −22 2
HR (beats/min) 75+ −31 77 3 + −1 30 0.495 62+ −22 2
10 min standing
SBP (mmHg) 109+ −4 15 113+ −4 28 0.509 100+ −32 2
DBP (mmHg) 72+ −21 57 3 + −2 28 0.755 69+ −22 2
HR (beats/min) 115+ −6 15 122+ −3 28 0.244 85+ −22 2
Total standing time (min) 21+ −21 72 0 + −2 30 0.902 27+ −22 2
 HR at maximal tolerance (beats/min)∗ 40+ −41 75 1 + −3 30 0.030 26+ −32 2
Valsalva manoeuvre†
Early phase II  SBP (mmHg) −24+ −41 7 −24+ −3 27 0.838 −14+ −32 1
Late phase II  SBP (mmHg)‡ 11+ −21 71 8 + −3 27 0.041 10+ −22 1
Phase II  HR (beats/min) 37+ −41 74 2 + −3 27 0.642 25+ −32 1
Phase IV overshoot  SBP (mmHg) 31+ −51 73 6 + −3 30 0.298 12+ −32 1
Valsalva manoeuvre ratio 1.95+ −0.41 17 2.01+ −0.06 30 0.580 1.62+ −0.07 21
Cold pressor  SBP (mmHg)† 20+ −21 72 0 + −2 29 1.000 20+ −32 0
LFRRI (ms2) 371+ −92 17 564+ −97 30 0.293 921+ −161 22
HFRRI (ms2) 322+ −109 17 338+ −58 30 0.598 1372+ −321 22
LFRRI/HFRRI 2.0+ −0.3 17 2.3+ −0.2 30 0.406 1.1+ −0.2 22
LFSBP (mmHg2)4 . 8 + −1.0 17 6.3+ −0.7 30 0.019 3.5+ −0.6 22
Plasma noradrenaline (pg/ml)
Supine 173+ −27 17 203+ −27 30 0.232 189+ −15 22
Upright 779+ −131 17 635+ −51 30 0.587 388+ −18 22
∗HR changes ( HR) from supine to standing at the time of maximal orthostatic tolerance.
†BP and HR responses are given as the change ( ) compared with baseline.
‡BP recovery from early to late phase II of the Valsalva manoeuvre.
There was no signiﬁcant difference in the calculated
erythocyte volume between CFS and non-CFS–
POTS patients (1334+ −74 compared with 1331+ −72 ml
respectively; P=0.980). Both groups experienced a
signiﬁcant deﬁcit in erythocyte volume compared with
normative data [−330+ −30 ml (20.2+ −1.9%) compared
with −302+ −65 ml (18.4+ −3.9%) in the CFS–POTS and
non-CFS–POTSgrouprespectively;P=0.657],butwere
not different from each other.
The calculated total BV was similar between
CFS–POTS and non-CFS–POTS patients (3878+ −137
compared with 4118+ −184 ml respectively; P=0.341).
There was no signiﬁcant difference in the calculated
deﬁcit from predicted values in total BV between
the CFS and non-CFS–POTS groups (−441+ −82
compared with −338+ −154 ml respectively; P=0.526).
The percentage deﬁcit in total BV for the non-CFS–
POTS group was borderline (−7.7+ −3.5%; normal
range, 0–8%), whereas patients with CFS–POTS had a
mild deﬁcit (−10.4+ −2%; mild deﬁcit range, 8–16%).
This difference in percentage deﬁcit, however, was not
statistically signiﬁcant (P=0.468). The proportion of
subjects with deﬁcits in total BV was non-signiﬁcantly
higher in the CFS–POTS group compared with the non-
CFS–POTS group (55 compared with 37%).
QSART
Abnormal QSART results were observed in 52% of
CFS–POTS patients tested (11 of 21) and 50%
of patients with non-CFS–POTS (5 of 10). In both
groups, the most affected sites were the foot [81%
of CFS–POTS (n=9) and 80% of non-CFS–POTS
(n=4)] and the distal leg [64% of CFS–POTS (n=7)
and 100% of non-CFS–POTS (n=5)]. The forearm was
the least affected site in both CFS and non-CFS–POTS
patients [27% (n=3) and 20% (n=1) respectively]. The
most common pattern seen in both groups was a distal
pattern affecting two to three sites (four CFS–POTS
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Figure 2 Orthostatic changes in (A) PRA, (B) plasma
aldosterone and (C) the aldosterone/PRA ratio in patients
with CFS and non-CFS–POTS
Control values from the Vanderbilt Autonomic Dysfunction Center database are
included for reference. Values are expressed as means+ −S.E.M. The reported P
values are for Mann–Whitney U tests comparing CFS–POTS with non-CFS–POTS
patients.
and two non-CFS–POTS patients). However, there
were not signiﬁcant differences in mean sweat volumes
between patients with CFS–POTS and non-CFS–POTS
at the four standard sites: forearm (0.73+ −0.13 compared
with 0.64+ −0.19 L; P=0.760), proximal leg (0.61+ −0.09
compared with 0.47+ −0.08 litre; P=0.347), distal leg
(0.63+ −0.11 compared with 0.36+ −0.09 litre; P=0.476)
and foot (0.40+ −0.07 compared with 0.33+ −0.08 litre;
P=0.416).
DISCUSSION
The main ﬁndings from this study were that: (i) the
majority of patients with POTS fulﬁlled the criteria
for CFS. Furthermore, severe fatigue and CFS-deﬁning
symptoms were also common features in POTS patients
not meeting criteria for CFS; (ii) the pattern of CFS
symptoms was similar in both groups, although as
expected some CFS-deﬁning symptoms were more
prevalent in patients with CFS–POTS; (iii) physical
functioning was similarly low in both groups, despite
more severe fatigue in CFS–POTS patients; (iv) CFS–
POTS patients had higher markers of sympathetic
overactivity, including increased orthostatic tachycardia,
restinglow-frequencySBP,andgreaterBPrecoveryduring
late phase II of the Valsalva manoeuvre and higher supine
and upright PRA; (v) POTS patients with and without
CFSshowedasimilarmilddecreaseinerythocytevolume
and borderline deﬁcit in total BV; and (vi) Sudomotor
abnormalities were frequent in both groups, with no
differences in the pattern of sudomotor denervation
or sweat volumes. These ﬁndings suggest that CFS–
POTS is not a separate clinical entity distinct from non-
CFS–POTS. We propose that CFS–POTS is part of
the spectrum of this syndrome, associated with greater
sympathetic activation and/or a more severe form of this
condition.
Fatigue is often a major complaint of patients with
POTS and, in some patients, can be chronic and
overwhelming [15]. Thus, a substantial overlap between
POTS and CFS has been consistently reported in
the literature [10,11,15,16,18]. Most of these studies,
however, have focused on the clinical features of
orthostatic intolerance in patients with CFS. It is, as yet,
unclear if and to what extent the hallmark symptoms
of CFS are also main features of POTS. To address this
question, we evaluated CFS symptoms in patients with
POTS,andcomparedtheCFSphenotypeofsubjectswith
POTS who met CFS criteria with those who did not. We
found that severe fatigue was highly prevalent in patients
with POTS, even among subjects who did not meet the
criteria for CFS. Only three out of 44 patients reported
levelsoffatiguecomparablewithhealthysubjects(<36in
the CIS, fatigue subscale) [30]. Accordingly, the majority
of our POTS patients (64%) met the CDC criteria
for CFS. This is in contrast with previous studies in
which the prevalence of fatigue (48–77%), and subjects
fulﬁlling CFS criteria (17–23%) were lower [15,17,18].
Possibleexplanationsforthesediscrepanciesmayinclude
differences in methods of symptom assessment (chart
review compared with validated questionnaires), clinical
heterogeneity of POTS patients or patient selection bias.
In this regard, because we are a tertiary referral centre for
the management of these disorders, it is possible that we
preferentiallyenrolpatientsseverelyaffectedwithPOTS,
which may explain the high prevalence of fatigue.
CFS-related symptoms followed the same pattern
in both POTS groups. Although there were some
differences in the prevalence of symptoms such as
unrefreshing sleep, muscle pain, post-exertional fatigue
and headaches; we could not ﬁnd a distinctive clinical
presentation of CFS in POTS. Moreover, the pattern
of CFS symptoms in our cohort was similar to that
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observed in large international epidemiological and
clinical datasets [22,31], raising the possibility that
common pathophysiological mechanisms may underlie
CFS-related symptoms in POTS and other CFS
populations. We also found greatly impaired physical
functioning in both groups, despite greater fatigue in
POTS patients with CFS. Costigan et al. [32] observed
that a higher burden of orthostatic symptoms was the
only factor independently associated with functional
impairment in CFS patients. Hence, we speculate that
orthostaticintoleranceinPOTSmaybeamoreimportant
determinantoffunctionalimpairmentthanfatigue.Taken
together, these ﬁndings suggest that POTS is a symptoms
complex that is not only associated with orthostatic
intolerance, but is also associated with CFS symptoms
that may arise from a common pathophysiology.
Several studies have shown enhanced sympathetic
activityinCFSpatientsascomparedwithhealthysubjects
[4,33,34], and the same was true in POTS patients; those
who met CFS criteria had higher markers of sympathetic
activity. The orthostatic tachycardia in POTS is easily
explained by this increase in sympathetic activity and the
corresponding decrease in vagal tone evidenced by
the decrease in high frequency power spectra of HR. It is
less clear how, or if, sympathetic activation relates to the
symptoms of fatigue, and this may be an area of future
research.
Supine and upright PRA were higher in CFS–POTS
than in non-CFS–POTS patients. Low BV is normally a
potent stimulus for renin release, and in our patients,
BVs were similarly low in both groups, but tended
to be lower in the CFS–POTS group. Aldosterone,
on the other hand, was similar in both groups, so
that there was a trend towards lower aldosterone/PRA
ratios in the CFS–POTS group, suggesting decreased
aldosterone responsiveness to PRA stimulation [21].
These ﬁndings raise the possibility that impairment of
the RAAS (renin–angiotensin–aldosterone system) may
contribute to the lower BVs in CFS–POTS [21], and
the higher PRA may be a compensatory response to
more severe hypovolaemia [35]. Given the results of
the autonomic testing in CFS–POTS, which pointed
to enhanced sympathetic activation, it is tempting to
speculate that the increased PRA in this group may be,
at least in part, the result of enhanced renal sympathetic
activation. Similar results were reported by Wyller et al.
[36], who found higher PRA in adolescents with CFS
as compared with healthy subjects. Garland et al.
[13] showed that POTS patients with higher supine
PRA also had higher orthostatic tachycardia, and lower
aldosterone/PRA ratio as compared with POTS with
lower supine PRA. Nevertheless, we cannot exclude the
possibility that the differences in PRA between groups
may be due to differences in other components of RAAS
such as AngII (angiotensin II), which has been shown to
be increased in some patients with POTS [37].
A partial autonomic neuropathy has been proposed as
playing a role in the pathophysiology of POTS [18]. We
used QSART to assess the integrity of postganglionic
cholinergic sudomotor ﬁbres [15,28]. Patients with
CFS–POTS and non-CFS–POTS had a similar high
prevalence of abnormal sudomotor responses (52 and
50% respectively), which is in agreement with the
prevalence reported in other POTS cohorts [15,28].
We excluded patients who were bedridden or severely
deconditioned from the present study. Nonetheless, we
cannot rule out that milder forms of cardiovascular
deconditioning may contribute to the abnormalities
observed in POTS [8,35,38]. Deconditioning, however, is
unlikely to explain the differences between CFS–POTS
and non-CFS–POTS because functional impairment was
similar in both groups. Another limitation of this study
is the potential referral and selection bias towards the
most severe cases of POTS, which may have had an
impact on the prevalence of fatigue- and CFS-related
symptoms. Also, we did not control for the phase of
the menstrual cycle in which patients were evaluated.
However,inapreviousstudy,themenstrualcycledidnot
affect orthostatic HR responses, BV or PRA at 30 min on
standing in POTS women [35]. Finally, a relatively small
number of non-CFS–POTS patients were included in the
BV assessments that may have introduced a type II error
(false negative results).
In conclusion, patients with CFS–POTS and non-
CFS–POTS had a similar clinical, autonomic and
neurohumoral proﬁle. Severe fatigue and CFS-related
symptomswerecommonfeaturesinpatientswithPOTS,
and the majority of them fulﬁlled the criteria for CFS.
Both groups showed a similar CFS phenotype with some
differences in the relative prevalence of case-deﬁning
symptoms. CFS in POTS, however, was associated with
the evidence of increase sympathetic tone when supine,
and greater increases in sympathetic activity and PRA
during standing. Because there were no distinguishing
features between POTS patients with and without CFS,
we propose that CFS–POTS is not a separate clinical
entity distinct from POTS without CFS. Rather, CFS
seems to be part of the spectrum of POTS, associated
with greater sympathetic activation and/or a more severe
formofthiscondition.Infuturestudies,pharmacological
approaches aimed at reducing this sympathetic activation
could be used to determine if it has a causative role in
the fatigue, and may represent a novel approach to the
treatment of CFS–POTS patients.
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